Investment Thesis
Vanda Pharmaceuticals is a cash-burning pharmaceutical company with zero revenue growth, severe operating losses (-$97.1% margin), and unsustainable negative free cash flow (-$50.4M). Despite maintaining $54M in liquidity and no debt, the company's burn rate will deplete cash within 12 months at current trends. Without demonstrated revenue growth or a clear path to profitability, fundamental operations are critically impaired.
Strengths
- Maintains adequate short-term liquidity with $54M cash and 2.16x current ratio
- Zero long-term debt (0.00x debt-to-equity) reduces near-term refinancing pressure
- Operates in pharmaceutical sector with potential upside if pipeline products achieve regulatory approval
Risks
- Unsustainable cash burn: -$50.4M free cash flow against only $54M cash implies <12 month runway at current burn rate
- Complete operational failure: -$50.2M operating loss on $51.7M revenue with -97.1% operating margin
- Zero revenue growth (0.0% YoY) indicates stagnant demand, competitive displacement, or market rejection
Key Metrics to Watch
- Quarterly revenue trends and new product commercialization timelines
- Operating cash flow trajectory and actual cash burn rate vs. projections
- Debt issuance or equity financing announcements indicating liquidity needs
Financial Metrics
Revenue
51.7M
Net Income
-48.6M
EPS (Diluted)
$-0.82
Free Cash Flow
-50.4M
Total Assets
433.5M
Cash
54.0M
Profitability Ratios
Gross Margin
117.7%
Operating Margin
-97.1%
Net Margin
-93.9%
ROE
-17.3%
ROA
-11.2%
FCF Margin
-97.5%
Balance Sheet & Liquidity
Current Ratio
2.16x
Quick Ratio
2.15x
Debt/Equity
0.00x
Debt/Assets
35.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T13:00:13.727641 |
Data as of: 2026-03-31 |
Powered by Claude AI